Poslední změna: 19.11. 2021

Extraordinary measure of the Czech Ministry of Health

From 15.  11. 2021 an extraordinary measure of the Czech Ministry of Health comes to effect. It states that:
  • It´s possible to enter healthcare facilities only for students with complete covid-19 vaccination, or those who had covid-19 within past 180 days (i.e. 180 days from the first possitive test).
  • Other students can enter the healthcare facilities only after an antigenic examination for SARS-CoV-2 virus via quick antigenic tests (RAT) performed till 22. 11. 2021 the latest, then performed once a 7 days.
Students, who don´t provide a vaccination certificate or don´t prove having covid-19 within past 180 days or don´t show this non-infectiouness test, won´t be allowed to practical classes in the University Hospital in Hradec Králove or any other healthcare facility. Missing attendance on tuition for this reason is not excusable.

Proof of valid completed covid-19 vaccination means:

Evidence by a national vaccination certificate or a certificate issued in accordance with the European Union Regulation on the EU digital certificate COVID1, provided that at least 14 days have elapsed since the completed vaccination schedule; a national certificate of vaccination is considered to be a written certificate issued at least in English by an authorized person operating in a third country, a model of which is published in the list of recognized national certificates on the website of the Ministry of Health; the written certificate must contain details of the person to be vaccinated, the type of vaccine administered, the date of vaccine administration, the identification of the person who issued the certificate and these data must be verifiable by remote access directly from the written certificate, provided that vaccination has been carried out:
  • a medicinal product containing a covid-19 vaccine which has been granted a marketing authorization in accordance with Regulation (EC) No 726/2004, or
  • a medicinal product the manufacture of which complies with the patent of the medicinal product referred to in point (i), provided that the medicinal product is also approved by the World Health Organization for emergency use